PubRank

David J Bearss

Author PubWeight™ 39.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A 2002 9.60
2 An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2012 3.48
3 Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002 2.55
4 The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 2002 2.39
5 Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 2011 1.88
6 The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther 2004 1.65
7 Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004 1.24
8 Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2003 1.23
9 Telomere inhibition and telomere disruption as processes for drug targeting. Annu Rev Pharmacol Toxicol 2002 1.17
10 Telomeres and telomerases as drug targets. Curr Opin Pharmacol 2002 1.14
11 High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. J Med Chem 2013 0.98
12 Retracted Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proc Natl Acad Sci U S A 2004 0.97
13 S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther 2010 0.94
14 Use of a bacteriophage lysin to identify a novel target for antimicrobial development. PLoS One 2013 0.93
15 Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS Med Chem Lett 2011 0.93
16 Laminin-5 beta3A expression in LNCaP human prostate carcinoma cells increases cell migration and tumorigenicity. Neoplasia 2004 0.92
17 Activators of PKM2 in cancer metabolism. Future Med Chem 2014 0.89
18 Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther 2003 0.84
19 Chemical genetic screen reveals a role for desmosomal adhesion in mammary branching morphogenesis. J Biol Chem 2012 0.84
20 Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther 2006 0.84
21 Structure-based design of novel anti-cancer agents targeting aurora kinases. Curr Med Chem Anticancer Agents 2003 0.82
22 TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res 2013 0.82
23 p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors. Mol Cancer Ther 2003 0.80
24 Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice. Pancreas 2008 0.80
25 In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Exp Hematol 2010 0.79
26 Competitive enhancement of HGF-induced epithelial scattering by accessory growth factors. Exp Cell Res 2010 0.78
27 Patterns and Significance of PIM Kinases in Urothelial Carcinoma. Appl Immunohistochem Mol Morphol 2015 0.75
28 Potential mouse tumor model for pre-clinical testing of mage-specific breast cancer vaccines. Breast Cancer Res Treat 2002 0.75
29 Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proc Natl Acad Sci U S A 2005 0.75